13
October

08:00 AM CEST

Medicinal Chemistry

Strategy Meeting Europe 2022

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Radisson Blu Hotel, Zurich Airport

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across Europe, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across Europe, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our 2022 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our 2022 Medicinal Chemistry strategy meeting.

Lurong Pan

Founder and CEO Ainnocence

Asif Ahmed

Executive Chairman and CEO MIRZYME

Professor Asif Ahmed is a world-renowned vascular scientist, who established Aston Medical School and is the founder of <a href="https://www.mirzyme.com/">MirZyme Therapeutics</a>, a biopharmaceutical company developing diagnostics and drugs to address the unmet medical needs and prevent disorders of pregnancy. He discovered two protective pathways that put the ‘brakes’ on preeclampsia; a life-threatening condition in pregnancy. He has championed social mobility, international connectivity and translational research. Before becoming the inaugural Pro-Vice-Chancellor for Health in 2012, he was the Gustav Born Chair of Vascular Biology at the University of Edinburgh. He is the recipient of the 7th British Muslim Awards for ‘Services to Education’ in 2019.
Founder of <a href="https://www.mirzyme.com/">MirZyme Therapeutics</a> with globally granted patents to prevent preeclampsia. Discoverer of two protective pathways to stop preeclampsia during pregnancy. Founder of the most socially inclusive medical school in the United Kingdom.
Professor Ahmed is a research-minded visionary communicator and possesses entrepreneurial energy and the ability to identify opportunities for growth. He helps to shape the future direction of organisations with his ability to empower others and encourage them to make meaningful contributions to the organisation and wider society.
Most of Professor Ahmed’s academic life was spent in top research-intensive universities. He moved to Aston to bring about a transformational change in Birmingham by establishing the most socially inclusive medical school in the United Kingdom. He wanted to ensure that the school had innovative medical education, inclusive leadership, and a focus on research at the core of its model, but did not compromise entry standards in selecting students from hard-to-reach backgrounds. His message to his medical school staff was simple “Inspire to Aspire”.
Professor Ahmed’s drive is to ensure that his discoveries translate so that no woman who chooses to have a baby ever needs to fear the silent killer preeclampsia. MirZyme and Professor Ahmed are leading a targeted therapeutic approach to prevent preeclampsia.

Daniel Gironés

Senior Vice President Drug Discovery Protinhi Therapeutics

Edgar Jacoby

Senior Principal Scientist Computational Chemistry The Janssen Pharmaceutical Companies of Johnson & Johnson

Henrik Keränen

Research Scientist and Head of Computational Chemistry Section Lundbeck

Guido Koch

Chief Executive Officer Amphilix AG

Guido Koch is a board member of SynpleChem and co-founder and CEO of <a href="https://www.amphilix.com/">Amphilx</a>. From 2018 to 2020, Guido was the COO of Topadur Pharma and before a Director in Global Discovery Chemistry at Novartis.
During his career in drug discovery and development, Guido has lead projects in different phases from target identification to early clinical stage including multiple kinase inhibitors. Highlights from >20 years of experience in pharmaceutical industry include significant contributions to one marketed product and 8 clinical candidates.
Guido has built a strong network with academia and the CRO community, which allows him to support research programs by external knowledge, new technology and resources. His research has culminated in >45 scientific publications and 10 patent applications.
Educated at ETH Zürich, he received his Diploma in Chemistry and Biochemistry in 1991, followed from a PhD from the University of Basel. After a postdoc at Caltech, he joined Novartis in 1997.

Philippe Pinton

Vice-President, Global Head of Translational Medicine and Clinical Pharmacology Ferring Pharmaceuticals

Philippe Pinton has over 20 years’ experience in the Pharmaceutical Industry across Research & Development and Medical Affairs, in Asia, Europe and the USA, in major pharmaceutical companies. Philippe Pinton is Vice-President, Global Head of Translational Medicine and Clinical Pharmacology at <a href="https://www.ferring.com/">Ferring Pharmaceuticals</a>. He graduated from the universities of Lille and Paris, and from the HEC business school (France). Prior to joining the Industry, he was a resuscitation ward hospital practitioner. 
His recent works explored auto-immune or inflammatory diseases and oncology, developing in silico clinical studies and computational models integrating multiple omics to better understand patients’ treatment response and comorbidome.

Stefan Schiesser

Associate Principal Scientist AstraZeneca

See the complete agenda and facilitator line-up

Download the strategy meeting brochure for full details

DOWNLOAD BROCHURE

Who Should Attend the Event?

Chief Executive Officers

Executive Vice Presidents

Vice Presidents

Executive Directors

Directors

Global Heads

Responsible For: